ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
about
Molecular aspects of prostate cancer with neuroendocrine differentiationEvolution of the cancer genomeN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerIdentification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal originThe HOPE fixation technique--a promising alternative to common prostate cancer biobanking approaches.Advancing a clinically relevant perspective of the clonal nature of cancerHistone modifications are associated with transcript isoform diversity in normal and cancer cellsThe role of HOXC6 in prostate cancer development.Personalized management in low-risk prostate cancer: the role of biomarkers.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.Diagnostic and prognostic molecular biomarkers for prostate cancer.ERG protein expression as a biomarker of prostate cancer.Small cell carcinoma of the prostate.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerComparison of different prostatic markers in lymph node and distant metastases of prostate cancer.Liquid biopsy: ready to guide therapy in advanced prostate cancer?Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.Ecotropic viral integration site 1, a novel oncogene in prostate cancer.Potential for targeted therapy in prostate cancers with ERG abnormalities.ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimensERG gene rearrangements are common in prostatic small cell carcinomas.Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.Prognostic significance of phospho-histone H3 in prostate carcinoma.ERG expression and prostatic adenocarcinoma.Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.Prognostic significance of YWHAZ expression in localized prostate cancer.Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancerSarcomatoid carcinoma of the prostate:ERGfluorescencein-situhybridization confirms epithelial origin
P2860
Q26752910-AE1B0646-30C4-4951-BD0C-A43F1D345BCEQ28678232-8C59D228-E28A-423C-AD40-2E5E9DD5906EQ28771715-F3FB351E-FB7C-4921-A4EB-AD07F5E50B55Q30887494-3431D719-2700-42A6-933B-B511A019FF77Q31005436-60216850-49F3-4877-AB11-F28F2507707DQ34093988-5D999F3E-FD3A-437B-B7E3-850376422858Q35123202-0F10274B-6393-4816-BF2C-E841DC50D0FDQ35182079-2A767E9A-2617-4796-8442-58411D322C98Q35756663-9D53B204-49E1-431F-9A9A-7603EBEF4196Q36495701-598B4CBE-983A-4DC9-8CBD-108AB98D6E9DQ36688923-950BA2F8-6EC6-4741-86B3-DCB2C19A5171Q36888450-2A2FFC3E-99C2-4FF8-9F5D-4E7D47FBC91AQ36901964-14E23135-6761-447F-93C6-F99E40F4CB8FQ37268937-5E827247-CE4F-4960-B16E-44FD631E097CQ37972703-298279D9-F7D7-4802-AA0B-DA8B28CD986FQ38165243-52F6AE2C-13C5-4037-99E6-1D3056426D9CQ38188869-B6B10C87-2B14-4E95-A952-86D6E0C3E332Q38322114-D66EEB75-61FC-415A-86C7-2DA3F93263C6Q38391360-DB6C8C1C-1EFC-4547-AA01-D8267ADC0A5AQ38840458-8E152A4A-97D1-4A45-94CE-D9462AF08389Q38930827-6E74B3A5-4864-4458-9D90-D4746858C48CQ39175666-F299D1A9-09EB-4949-A108-8513E10B3656Q39182339-295D89C0-9A84-4049-B52A-2A1D9E9C5075Q39385550-BAEDF30A-A036-4B2F-9AAB-F29A81FCA2FAQ39401617-81593616-98C8-45B5-B790-8FC46488BB82Q39501622-3095EC45-C3CF-4120-9070-E726463972BEQ39666134-9414BC50-2D54-416B-8F1C-67D9AE429162Q40908009-69B9A05D-ADB1-4D8C-80DE-7A3F0AB7FBEBQ41052383-593424D1-11CA-453F-BED4-3CBD02FB4B5BQ41628946-04B003D6-4D8B-4D67-A530-81083C31D88CQ42350997-CECFB7B4-FCC0-4BB2-899D-126C13FA7530Q43247408-CF85D99E-0055-458F-96AF-E4B1005B1AEEQ45968823-A904D435-716A-4B59-B402-4C47DC234DDEQ47355331-57E24BF0-0EDA-4B61-82EC-445732A7D6A7Q47931762-A155FB81-39CD-4B91-89EE-7D8A6870A0A2Q50964849-E7351294-C47F-49E1-B7A5-17E14F0D675EQ53628430-0556B67F-4BDD-40F0-92AA-16BBEB089D23Q55058481-A1ACEBC0-C27C-40E6-8E03-0E78BD38C330Q57693358-172CA643-1317-4A9E-811A-B804D108A82EQ57693868-C9022388-5E2D-414A-A15A-C0E58C9CEC9F
P2860
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
ERG rearrangement is specific ...... cur in any other common tumor.
@ast
ERG rearrangement is specific ...... cur in any other common tumor.
@en
type
label
ERG rearrangement is specific ...... cur in any other common tumor.
@ast
ERG rearrangement is specific ...... cur in any other common tumor.
@en
prefLabel
ERG rearrangement is specific ...... cur in any other common tumor.
@ast
ERG rearrangement is specific ...... cur in any other common tumor.
@en
P2093
P2860
P50
P1433
P1476
ERG rearrangement is specific ...... cur in any other common tumor.
@en
P2093
Ann-Cathrin Stiedl
Christian Ruiz
David Schilling
Glen Kristiansen
Karen Petersen
Lukas Bubendorf
Markus Reischl
Martin Braun
Rainer Kuefer
Rameen Beroukhim
P2860
P2888
P304
P356
10.1038/MODPATHOL.2010.87
P577
2010-05-14T00:00:00Z